Tricia Breeger Named CEO of Mitsubishi Electric Power Products, Inc.
WARRENDALE, Pa.–(BUSINESS WIRE)–Mitsubishi Electric Power Products, Inc., (MEPPI) today announced current President Tricia Breeger as…
Month: April 2023
april Launches AI-Driven Tax Solution, Disrupting Archaic Tax System to Usher in a Consumer-Friendly Future
In partnership with Acorns, Mercury Financial, B9, Moves, and others april is embedding AI-powered tax…
Morgan Stanley Capital Partners Enters Agreement to Sell Ovation Fertility to US Fertility
NEW YORK–(BUSINESS WIRE)–Investment funds managed by Morgan Stanley Capital Partners (“MSCP”), the middle-market focused private…
INmune Bio, Inc. Announces Submission of Investigational New Drug (IND) Application for INKmune™ to the U.S. Food and Drug Administration for Treatment of Metastatic Castration-Resistant Prostate Cancer
BOCA RATON, Fla., April 03, 2023 (GLOBE NEWSWIRE) — INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a…
INmune Bio, Inc. Announces Submission of Investigational New Drug (IND) Application for INKmune™ to the U.S. Food and Drug Administration for Treatment of Metastatic Castration-Resistant Prostate Cancer
BOCA RATON, Fla., April 03, 2023 (GLOBE NEWSWIRE) — INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a…
Aerami Therapeutics to Host Virtual Investor Day with Leading Experts in Pulmonary Hypertension as AER-901 (Inhaled Imatinib) Advances Toward Phase 2
DURHAM, N.C., April 03, 2023 (GLOBE NEWSWIRE) — Aerami Therapeutics (“Aerami”), a clinical stage biopharmaceutical…
Aerami Therapeutics to Host Virtual Investor Day with Leading Experts in Pulmonary Hypertension as AER-901 (Inhaled Imatinib) Advances Toward Phase 2
DURHAM, N.C., April 03, 2023 (GLOBE NEWSWIRE) — Aerami Therapeutics (“Aerami”), a clinical stage biopharmaceutical…
Celularity Receives U.S. Food And Drug Administration (FDA) Preliminary Assessment For Celularity’s Investigational Fuse Bone Void Filler To Be Regulated As A Device By FDA’s Center For Devices And Radiological Health
Celularity’s Pre-Request for Designation (Pre-RFD) is based on data demonstrating 100 percent biochemical characterization of…
Celularity Receives U.S. Food And Drug Administration (FDA) Preliminary Assessment For Celularity’s Investigational Fuse Bone Void Filler To Be Regulated As A Device By FDA’s Center For Devices And Radiological Health
Celularity’s Pre-Request for Designation (Pre-RFD) is based on data demonstrating 100 percent biochemical characterization of…
Enochian BioSciences’ CEO Letter to Shareholders
Turning the Page; A Promising Future LOS ANGELES, April 03, 2023 (GLOBE NEWSWIRE) — (NASDAQ:…
Enochian BioSciences’ CEO Letter to Shareholders
Turning the Page; A Promising Future LOS ANGELES, April 03, 2023 (GLOBE NEWSWIRE) — (NASDAQ:…
Panbela Announces New Research Agreement with Johns Hopkins University School of Medicine
MINNEAPOLIS, April 03, 2023 (GLOBE NEWSWIRE) — Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage…
Panbela Announces New Research Agreement with Johns Hopkins University School of Medicine
MINNEAPOLIS, April 03, 2023 (GLOBE NEWSWIRE) — Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage…
Ashvattha Therapeutics to Present Preclinical Data at the AACR and ARVO 2023 Annual Meetings
Preclinical data to be presented at AACR will showcase the potential effect of D-4559, a…
Ashvattha Therapeutics to Present Preclinical Data at the AACR and ARVO 2023 Annual Meetings
Preclinical data to be presented at AACR will showcase the potential effect of D-4559, a…
RespireRx Pharmaceuticals Inc. Discloses Novel Structural Analogs of its GABAA Receptor Potentiator, KRM-II-81 with Antiseizure Efficacy and Antitremor Effects without Sedation.
Glen Rock, N.J., April 03, 2023 (GLOBE NEWSWIRE) — RespireRx Pharmaceuticals Inc. (OTC Markets: RSPI)…
RespireRx Pharmaceuticals Inc. Discloses Novel Structural Analogs of its GABAA Receptor Potentiator, KRM-II-81 with Antiseizure Efficacy and Antitremor Effects without Sedation.
Glen Rock, N.J., April 03, 2023 (GLOBE NEWSWIRE) — RespireRx Pharmaceuticals Inc. (OTC Markets: RSPI)…
CPI-818 Data Highlights Potential for ITK Inhibition as a New Immunotherapy Approach for the Treatment of T Cell Lymphoma
Interim data from Phase 1/1b clinical trial of CPI-818, including new evidence supporting the recently…
CPI-818 Data Highlights Potential for ITK Inhibition as a New Immunotherapy Approach for the Treatment of T Cell Lymphoma
Interim data from Phase 1/1b clinical trial of CPI-818, including new evidence supporting the recently…
ContraFect Announces Initiation of a Phase 1b/2 Study of Exebacase in Patients with Chronic Prosthetic Joint Infections of the Knee
YONKERS, New York, April 03, 2023 (GLOBE NEWSWIRE) — ContraFect Corporation (Nasdaq: CFRX), a clinical-stage…